title: Polyanion inhibitors of human immunodeficiency virus and other viruses. Part 2. Polymerized anionic surfactants derived from amino acids and dipeptides.
abstract: A series of new polyanions was synthesized via gamma-polymerization, in aqueous micellar solution, of omega-unsaturated anionic surfactants whose polar head was derived from amino acids or dipeptides. The obtained polyanions were evaluated for their activity against human immunodeficiency virus (HIV-1, HIV-2) and various other RNA and DNA viruses. All the test compounds proved active against HIV-1 and HIV-2, their 50% inhibitory concentration (IC50) being in the range of 0.04-7.5 micrograms/mL, while they were not toxic to the host cells (CEM-4 or MT-4) at concentrations up to 100 micrograms/mL or higher. The HIV-inhibitory effect increased with the hydrophilic character of the amino acid moiety. The compounds were found to interact with both the viral envelope glycoprotein gp120 and the cellular CD4 receptor, thus blocking virus-cell binding and virus-induced syncytium formation. These polyanions also proved active against human cytomegalovirus at about the same IC50 as for HIV. In addition, they were also active, albeit at somewhat higher IC50 values (0.8-20 micrograms/mL), against other enveloped viruses such as respiratory syncytial virus and arenaviruses (Junin and Tacaribe). At yet higher IC50 values ( > or = 20 micrograms/mL), some of the compounds showed activity against influenza A virus. No activity was observed with any of the compounds against vesicular stomatitis virus, Sindbis virus, Semliki forest virus, influenza B, parainfluenza type 3, and the nonenveloped viruses Coxsackie type B4, polio type 1, and reovirus type 1.
authors.affiliation: Laboratoire de Chimie Organique Physique, Universitè de Montpellier II, Cèdex 5, France.
authors.forename: A
authors.initials: A
authors.lastname: Leydet
authors.forename: H
authors.initials: H
authors.lastname: El Hachemi
authors.forename: B
authors.initials: B
authors.lastname: Boyer
authors.forename: G
authors.initials: G
authors.lastname: Lamaty
authors.forename: J P
authors.initials: JP
authors.lastname: Roque
authors.forename: D
authors.initials: D
authors.lastname: Schols
authors.forename: R
authors.initials: R
authors.lastname: Snoeck
authors.forename: G
authors.initials: G
authors.lastname: Andrei
authors.forename: S
authors.initials: S
authors.lastname: Ikeda
authors.forename: J
authors.initials: J
authors.lastname: Neyts
authors.forename: D
authors.initials: D
authors.lastname: Reymen
authors.forename: J
authors.initials: J
authors.lastname: Este
authors.forename: M
authors.initials: M
authors.lastname: Witvrouw
authors.forename: E
authors.initials: E
authors.lastname: De Clercq
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000138:chemical synthesis* / Q000494:pharmacology; D002460:Cell Line; D004285:Dogs; D006678:HIV / Q000187:drug effects*; D006801:Humans; D013329:Structure-Activity Relationship; D013501:Surface-Active Agents / Q000138:chemical synthesis* / Q000494:pharmacology; D014779:Virus Replication / Q000187:drug effects
chemical_list: D000998:Antiviral Agents; D013501:Surface-Active Agents